Table 1 Baseline comparison between control group and diabetic retinopathy patients under initiation of anti-VEGF treatment
|
Control group (n = 19) |
Diabetic retinopathy (n = 19) | p-value | |
|---|---|---|---|
| Age (SD) |
64.4 (± 9.7) |
63.5 (± 9.3) | 0.7∆ |
| FAZ area mm2 |
0.184 (± 0.058) |
0.307 (± 0.133) | 0.008* |
| Perimeter mm2 |
1.753 (± 0.408) |
2.415 (± 0.692) | 0.002* |
| Choroid thickness µm |
317.8 (± 15.3) |
335.9 (± 39.1) | 0.07∆ |
| Choriocapillaris whole image density % |
68.4 (± 5.1) |
62.6 (± 6.1) | 0.003 ∆ |
| Choriocapillaris foveal area density % |
66.3 (± 9.8) |
61.2 (± 7.4) | 0.014* |
| Choriocapillaris parafoveal area density % |
68.2 (± 4.8) |
61.9 (± 6.6) | 0.002 ∆ |
| Retinal whole image density % |
50.7 (± 5.6) |
46.9 (± 5.1) | 0.04 ∆ |
| Retinal foveal area density % |
34.1 (± 6.1) |
27.6 (± 5.9) | 0.002 ∆ |
| Retinal parafoveal area density % |
53.1 (± 6.0) |
49.0 (± 5.6) | 0.011* |
| CST µm |
276.6 (± 22.9) |
397.1 (± 93.2) | < 0.0001* |
| Visual acuity ETDRS |
81.3 (± 4.6) |
69.7 (± 8.1) | < 0.0001* |